UCB today announced positive results for the two pivotal Phase III trials (PRECISE 1 and 2) of certolizumab pegol (CDP870) in the induction and maintenance of clinical response in moderate to severe active Crohn’TMs disease. The PRECiSE trials assessed the safety and efficacy of CIMZIATM compared to placebo over a 26 week period, in a total of 1330 patients with active Crohn’TMs disease.
Data from PRECiSE 1 and 2 will be presented in more detail at the major forthcoming gastroenterology medical congresses.
About Crohn’TMs Disease
Crohn’TMs disease is a chronic inflammatory disease of the gastrointestinal tract with the disease typically localized in the terminal part of the ileum (a portion of the small intestine) and right colon (a portion of the large intestine). Crohn’TMs disease affects almost 1 million patients worldwide, with the disease typically appearing early in life. Crohn’TMs disease is characterized by a variety of symptoms, although different in every individual, and may include persistent diarrhea, abdominal pain, and at times loss of appetite/weight, fever or rectal bleeding . Unfortunately there is no single test to diagnose Crohn’TMs disease and because it can often imitate other gastroenterological conditions, patients may experience a lengthy diagnosis process. Although Crohn’TMs disease affects males and females equally of all ages, the most affected in the U.S. are 20-29 year olds and 30-39 year olds . The disease also occurs in young children and adults over 70 years of age. In addition, American Jews of European backgrounds are more likely than the general population to develop Crohn’TMs disease.
Crohn’s Disease - United States (Prevalence)
Yrs of age 2005 %
0-9 30906 8%
10-19 32491 9
20-29 145598 39%
30-39 68205 18%
40-49 23525 6%
50-59 41850 11%
60-69 11669 3%
70-79 11656 3%
80+ 7131 2%
CIMZIATM is a PEGylated Fab’TM fragment of a humanized anti-TNF alpha monoclonal antibody, with high affinity for both soluble and membrane-bound TNF alpha. CIMZIATM is also currently the subject of Phase III clinical trials in rheumatoid arthritis.
UCB (www.ucb-group.com) is a global biopharmaceutical leader dedicated to the research, development and commercialization of innovative products in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders and oncology. UCB employs over 8,500 people operating in over 40 countries. UCB is listed on the Euronext Brussels with a market capitalization of approximately â‚¬ 5.8 billion. Worldwide headquarters are located in Brussels, Belgium.
UCB Pharma, Inc. is the North American subsidiary of UCB, with U.S. headquarters located in Smyrna, Georgia. UCB’TMs key products in the U.S. are Keppra® (levetiracetam), Zyrtec®’ (cetirizine HCl), Tussionex® CIII (hydrocodone polistirex/chlorpheniramine polistirex), and Metadate® CD CII (methylphenidate HCl, USP).
’ Zyrtec is licensed to and co-promoted with Pfizer, Inc. in the United States.
Lisa Garman | EurekAlert!
Gentle sensors for diagnosing brain disorders
29.09.2016 | King Abdullah University of Science and Technology
New imaging technique in Alzheimer’s disease - opens up possibilities for new drug development
28.09.2016 | Lund University
Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.
This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...
Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion
Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
26.10.2016 | Power and Electrical Engineering
26.10.2016 | Health and Medicine
26.10.2016 | Materials Sciences